File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Role of radiofrequency ablation for liver malignancies

TitleRole of radiofrequency ablation for liver malignancies
Authors
KeywordsAblation
Liver
Malignancies
Radiofrequency
Issue Date2005
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ASH
Citation
Surgical Practice, 2005, v. 9 n. 3, p. 94-103 How to Cite?
AbstractRadiofrequency ablation (RFA) is commonly used to treat unresectable malignant liver tumours. It can achieve effective local tumour control and the maximal normal liver parenchyma can be preserved. In recent years, there has been a tremendous expansion in the application of RFA for patients with malignant liver tumours. However, the therapeutic effect of this local ablation treatment needs to be balanced against its risks and possible local failure. The present review focuses on the role of RFA for liver malignancies, with special attention to the indication, approaches, complications, survival benefits, combination therapies and comparison with other treatment modalities. Despite favourable results of most clinical studies of RFA, the associated risks and tumour recurrence of this treatment modality should not be underestimated. Careful patient selection, meticulous RFA techniques, and prompt treatment of residual and recurrent tumours are necessary to ensure a better outcome after RFA. Until recently, there has been no strong evidence showing that RFA can replace any other treatment modalities in the management of liver tumours. Nonetheless, more convincing evidence by randomized trials is required for the establishment of a treatment protocol of RFA for patients with liver malignancies.
Persistent Identifierhttp://hdl.handle.net/10722/172880
ISSN
2013 Impact Factor: 0.172
2015 SCImago Journal Rankings: 0.121
References

 

DC FieldValueLanguage
dc.contributor.authorNg, KKCen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2012-10-30T06:25:30Z-
dc.date.available2012-10-30T06:25:30Z-
dc.date.issued2005en_US
dc.identifier.citationSurgical Practice, 2005, v. 9 n. 3, p. 94-103en_US
dc.identifier.issn1744-1625en_US
dc.identifier.urihttp://hdl.handle.net/10722/172880-
dc.description.abstractRadiofrequency ablation (RFA) is commonly used to treat unresectable malignant liver tumours. It can achieve effective local tumour control and the maximal normal liver parenchyma can be preserved. In recent years, there has been a tremendous expansion in the application of RFA for patients with malignant liver tumours. However, the therapeutic effect of this local ablation treatment needs to be balanced against its risks and possible local failure. The present review focuses on the role of RFA for liver malignancies, with special attention to the indication, approaches, complications, survival benefits, combination therapies and comparison with other treatment modalities. Despite favourable results of most clinical studies of RFA, the associated risks and tumour recurrence of this treatment modality should not be underestimated. Careful patient selection, meticulous RFA techniques, and prompt treatment of residual and recurrent tumours are necessary to ensure a better outcome after RFA. Until recently, there has been no strong evidence showing that RFA can replace any other treatment modalities in the management of liver tumours. Nonetheless, more convincing evidence by randomized trials is required for the establishment of a treatment protocol of RFA for patients with liver malignancies.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ASHen_US
dc.relation.ispartofSurgical Practiceen_US
dc.subjectAblationen_US
dc.subjectLiveren_US
dc.subjectMalignanciesen_US
dc.subjectRadiofrequencyen_US
dc.titleRole of radiofrequency ablation for liver malignanciesen_US
dc.typeArticleen_US
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1744-1633.2005.00265.xen_US
dc.identifier.scopuseid_2-s2.0-23944506043en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23944506043&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue3en_US
dc.identifier.spage94en_US
dc.identifier.epage103en_US
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridNg, KKC=35248894000en_US
dc.identifier.scopusauthoridPoon, RTP=7103097223en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats